Cart
0

Moxifloxacin HCl (CAS 186826-86-8) Market by Product (Quality Grade 98.0%-99.5%, First Grade 99.5%-99.9%, and Excellence Grade 98.9%), by Dosage Type (Oral Drugs, Parenteral Drugs, and Ophthalmic Drugs), and by Application (Bronchitis, Pneumonia, Sinusitis, Pelvic Inflammatory Disease, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_182959
Pages: NA
Dec 2018 | 1028 Views
 
Author's : NA
Tables: NA
Charts: NA
 

A hydrolyzed salt of moxifloxacin and a fourth-generation antibiotic, Moxifloxacin HCl is used as broad-spectrum antibiotic, which is active against both gram-negative and gram-positive strains of bacteria. This antibiotic is used to treat respiratory tract infection, urinary tract infection, and other bacterial infections.

Factors such as increase in prevalence of bacterial diseases (such as respiratory infection, urinary tract infection, and pneumonia), rise in drug resistance, and low cost of products are expected to drive the market growth. In addition, growth in the number of therapeutic product applications fuels the growth of the moxifloxacin HCL market.

However, the side effects associated with antibiotic (such as abdominal discomfort, diarrhea, vomiting, nausea, and mouth sores) restrain the moxifloxacin HCL market.

The moxifloxacin HCl (CAS 186826-86-8) market is segmented based on product, application, and geography. By product, it is categorized into qualified grade: 98.0%-99.5%, first grade: 99.5-99.9% and excellence grade: 99.9%. By application, the market is classified into oral drugs, parenteral drugs, and ophthalmic drugs. Based on application, it is divided into bronchitis, pneumonia, sinusitis, pelvic inflammatory disease, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the moxifloxacin HCl (CAS 186826-86-8) market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to determine various products available in the market.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.

Moxifloxacin HCl (CAS 186826-86-8) Market key SEGMENTS:

By Product

  • Qualified Grade: 98.0%-99.5%
  • First Grade: 99.5-99.9%
  • Excellence Grade: 99.9%

By Dosage Type

  • Oral
  • Parenteral
  • Ophthalmic Drugs

By Application

  • Bronchitis
  • Pneumonia
  • Sinusitis
  • Pelvic Inflammatory Disease
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

List of players profiled in the report

  • Bayer Healthcare
  • Rivopharm UK Ltd.
  • Actavis UK
  • Cayman Pharmacy Groups
  • Pioneer Biotech
  • TECO land
  • BOC Sciences
  • Yutian Pharmaceutical
  • Nivika Chemo Pharma
  • Neuland laboratories Ltd.
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4.  PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 MOXIFLOXACIN HCL (CAS 186826-86-8) MARKET , BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. QUALIFIED GRADE: 98.0%-99.5%

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. FIRST GRADE: 99.5-99.9%

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. EXCELLENCE GRADE: 99.9%

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 MOXIFLOXACIN HCL (CAS 186826-86-8) MARKET , BY DOSAGE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ORAL

4.2.1. Market size and forecast

5.3. PARENTERAL

5.3.1. Market size and forecast

5.4. OPHTHALMIC DRUGS

5.4.1. Market size and forecast

Chapter: 6 MOXIFLOXACIN HCL (CAS 186826-86-8) MARKET , BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. BRONCHITIS

6.2.1. Market size and forecast

6.3. PNEUMONIA

6.3.1. Market size and forecast

6.4. SINUSITIS

6.4.1. Market size and forecast

6.5. PELVIC INFLAMMATORY DISEASES

6.5.1. Market size and forecast

6.7. OTHERS

6.7.1. Market size and forecast

Chapter: 7 MOXIFLOXACIN HCL (CAS 186826-86-8) MARKET , BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Moxifloxacin HCl (CAS 186826-86-8) Market by Product
7.2.5. North America EuropeMoxifloxacin HCl (CAS 186826-86-8) Market by Dosage Type
7.2.6. North America EuropeMoxifloxacin HCl (CAS 186826-86-8) Market by Application

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. EuropeMoxifloxacin HCl (CAS 186826-86-8) Market by Product
7.3.5. EuropeMoxifloxacin HCl (CAS 186826-86-8) Market by Dosage Type
7.3.6. EuropeMoxifloxacin HCl (CAS 186826-86-8) Market by Application

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-PacificMoxifloxacin HCl (CAS 186826-86-8) Market by Product
7.4.5. Asia-PacificMoxifloxacin HCl (CAS 186826-86-8) Market by Dosage Type
7.4.6. Asia-PacificMoxifloxacin HCl (CAS 186826-86-8) Market by Application

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Latin America market size and forecast
7.5.3.2. Middle East market size and forecast
7.5.3.3. Africa market size and forecast

7.5.4. LAMEAMoxifloxacin HCl (CAS 186826-86-8) Market by Product
7.5.5. LAMEAMoxifloxacin HCl (CAS 186826-86-8) Market by Dosgae Type
7.5.6. LAMEAMoxifloxacin HCl (CAS 186826-86-8) Market by Application

Chapter: 8 COMPANY PROFILES

8.1. BAYER HEALTHCARE

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. RIVOPHARM UK LTD.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ACTAVIS UK

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. CAYMAN PHARMACY GROUPS

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. PIONEER BIOTECH

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. TECO LAND

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. BOC SCIENCES

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. YUTIAN PHARMACEUTICAL

8.8.1. Operating business segments
8.8.2. Business performance

8.9. NIVIKA CHEMO PHARMA

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. NEULAND LABORATORIES LTD.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request TOC/Sample

Request Customization

Request TOC/Sample

OR

Purchase Full Report of
Moxifloxacin HCl (CAS 186826-86-8) Market- Global Opportunity Analysis and Industry Forecast, 2017-2025

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4833
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5805
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $8096
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo